enGene Holdings Inc (ENGN) Surging After Positive Phase 2 LEGEND Trial

​enGene Holdings Inc. (NASDAQ:ENGN) is one of the Best Up and Coming Canadian Stocks to Buy. enGene Holdings Inc. (NASDAQ:ENGN) has gained more than 31% since the company reported positive results from its Phase 2 LEGEND trial on November 11.

​Wall Street also maintains a positive outlook with analysts’ 12-month price target of $23 reflecting more than 190% upside from the current level. On November 12, David Dai from UBS reiterated a Hold rating on the stock with a $10 price target. On the same day, Judah Frommer from Morgan Stanley reiterated a Buy rating on the stock with a price target of $18.

​enGene Holdings Inc. (NASDAQ:ENGN) reported an improved complete response rate of 62% at 6 months of Detalimogene voraplasmid to treat high-risk, BCG-unresponsive non-muscle invasive bladder cancer. Management noted that at 3 months, the complete response rate was 56% However, at 6 months, the response rate improved to 62% among 37 patients.

​The preliminary data from the trial suggest that the company remains on track for its planned Biologics License Application submission in the second half of 2026.

​enGene Holdings Inc. (NASDAQ:ENGN) is a clinical-stage biotechnology company developing non-viral genetic medicines for the delivery of therapeutics to mucosal tissues and other organs.

While we acknowledge the potential of ENGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.